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Summary
A major issue in telomere research is to understand
how the integrity of chromosome ends is preserved
[1, 2]. The human telomeric protein TRF2 coordinates
several pathways that prevent checkpoint activation
and chromosome fusions [3–9]. In this work, we iden-
tified hSNM1B [10], here named Apollo, as a novel
TRF2-interacting factor. Interestingly, the N-terminal
domain of Apollo is closely related to that of Artemis,
a factor involved in V(D)J recombination and DNA re-
pair [11]. Both proteins belong to the b-CASP metallo-
b-lactamase family of DNA caretaker proteins [12, 13].
Apollo appears preferentially localized at telomeres in
a TRF2-dependent manner. Reduced levels of Apollo
exacerbate the sensitivity of cells to TRF2 inhibition,
resulting in severe growth defects and an increased
number of telomere-induced DNA-damage foci and
telomere fusions. Purified Apollo protein exhibits
a 50-to-30 DNA exonuclease activity. We conclude that
Apollo is a novel component of the human telomeric
complex and works together with TRF2 to protect
chromosome termini from being recognized and pro-
cessed as DNA damage. These findings unveil a previ-
ously undescribed telomere-protection mechanism
involving a DNA 50-to-30 exonuclease.
Results and Discussion
Apollo, a Paralog of Artemis, Interacts with TRF2
By using an N-terminal TRF2 fragment of 227 residues
as a bait in a two-hybrid screen of a human cDNA library,
we obtained one clone corresponding to a cDNA
*Correspondence: eric.gilson@ens-lyon.frencoding hSNM1B [10] (a detailed description of the
procedures used in this work can be found in the Sup-
plemental Experimental Procedures available with this
article online). hSNM1B is a paralog of two related pro-
teins: hSNM1A, possibly involved in the repair of DNA
inter-strand crosslinks [13], and Artemis, participating
in V(D)J recombination and DNA repair [11]. The inter-
action of SNM1B with TRF2 was recently reported by
Freibaum and Counter [14]. Because hSNM1B is more
closely related to Artemis than to hSNM1A, we called it
Apollo, the twin brother of Artemis in Greek mythology.
A C-terminal fragment of Apollo, containing amino acids
412–532, is necessary and sufficient for the interaction
with TRF2 (Figure 1A and data not shown).
To demonstrate the in vivo interaction between TRF2
and Apollo in mammalian cells, we transfected COS7
cells with either GST or GST-tagged human TRF2 to-
gether with Flag-Apollo [15]. Figure 1B shows that Flag-
Apollo copurified with GST-TRF2 but not with GST and
that the interaction between both partners is maintained
throughout increasingly stringent conditions of the
washes up to 0.5% NP40 and 1 M NaCl. To prevent
any copurification of both proteins through DNA, we
performed DNaseI treatment before the pull-down as-
say or added ethidium bromide throughout the assay.
The interaction was preserved in these conditions
(Figure 1C). Therefore, DNA does not seem to be neces-
sary for the in vivo interaction between Apollo and TRF2
in COS7 cells.
To further characterize the TRF2-Apollo interaction,
we used GST-fusion proteins containing truncated ver-
sions of TRF2 [15] (Figure 1D). Copurification of Flag-
Apollo is efficient with constructs containing either the
full-length TRF2 protein or the central part of TRF2,
but not with constructs in which either the basic N-termi-
nal or the C-terminal Myb-like telobox domains alone
are fused to GST (Figures 1E). Because the exogenous
GST-TRF2 might be able to heterodimerize with the en-
dogenous TRF2 expressed in COS 7 cells, one cannot
rule out the possibility that Apollo interacts with a do-
main of TRF2 located outside of or overlapping with
the central homodimerization domain. Altogether, these
data indicate that TRF2 associates with Apollo primarily
via its N-terminal domain (amino acids 1–227).
Flag-fusion proteins containing deletion mutants of
Apollo were also generated (Figure 1F). As shown in
Figure 1G, copurification of GST-TRF2 is efficient with
full-length Apollo and with its nonconserved C-terminal
domain but not with its b-lactamase-b-CASP N-terminal
domain. This is in full agreement with the results of the
two-hybrid assay.
Apollo Is a Component of the Human
Telomeric Complex
We failed to detect the endogenous Apollo protein by ei-
ther immunofluorescence or Western blot analysis with
homemade antibodies (data not shown), suggesting
that it is expressed at extremely low levels, in agreement
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1304Figure 1. Apollo Interacts with TRF2
(A) Schematic representation of TRF2 and Apollo. The bar underlining TRF2 indicates the part used as a bait in the yeast two-hybrid screen. The
bar underlining Apollo indicates the clone isolated in the two-hybrid screen.
(B) GST pull-down experiment with lysates from COS7 cells expressing exogenous Flag-Apollo and either GST or GST fused to TRF2. After pull
down, washes were performed with increasing stringency. The interaction was analyzed by immunoblot with anti-Flag and anti-GST.
(C) Interaction between Apollo and TRF2 in the presence of DNaseI (50 U) or ethidium bromide (40 mg/ml).
(D and E) Mapping of the Apollo-interacting domain in TRF2. Deletion mutants of TRF2 were expressed together with Flag-Apollo in COS7 cells,
and GST pull-down analysis followed.
(F and G) Mapping of the TRF2 interaction domain in Apollo. Flag-tagged deletion mutants of Apollo were generated and coexpressed in COS7
cells with GST-TRF2; the interaction was analyzed with GST pull-down assays.both with a previous report [10] and with the weakness
of the signal of Apollo mRNA we obtained in Northern
blots and in PCR experiments on cDNAs from several
human tissues (Figure S1 in the Supplemental Data avail-
able online). Therefore, in order to determine whether
Apollo is part of the telomeric complex in vivo, we used
a protein version fused with GFP at its C terminus.
Apollo-GFP appears to be functional because it comple-
ments the Apollo knockdown phenotype (see below).
When Apollo-GFP is transiently expressed in two telo-
merase-positive cell lines (293T and BJ-SV40-hTERT)
and in one telomerase-negative ALT line (GM847),
almost all the GFP-positive cells show bright nuclearfoci, which colocalize with the endogenous TRF1 and
TRF2 proteins (Figures 2Aa–o). Because TRF1 foci can
be considered good markers for interphase telomeres
[16, 17], Apollo-GFP appears to be concentrated at
telomeres of interphase cells. In a few GM847 cells,
Apollo-GFP also colocalizes with large foci containing
both TRF2 and PML, which are characteristic of the
ALT-associated PML bodies (Figures 2Ap–s).
Localizing Apollo to Telomeres Requires TRF2
To test for the involvement of TRF2 in the targeting of
Apollo to telomeres, we transfected Apollo-GFP con-
structs in cells expressing a dominant-negative allele,
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1307TRF2DBDM, which removes the endogenous TRF2
from telomeres [5]. In 69% of the GFP-positive nuclei,
Apollo-GFP foci disappeared while diffuse nuclear
fluorescence intensified (Figure 2B; compare a to d).
Because the TRF1 focal pattern is not greatly affected
by the expression of the dominant-negative allele of
TRF2 (Figures 2Bb and 2Be), we conclude that Apollo-
GFP is delocalized from telomeres when the binding of
TRF2 to the telomeres is compromised.
Knockdown of Apollo causes cell hypersensitivity to
inter-strand crosslink-inducing agents and radiation
[10], suggesting that this gene is involved in various
types of DNA-damage responses. This raises the possi-
bility that the delocalization of Apollo-GFP upon TRF2
inhibition could result from the activation of a cellular
response to DNA damage. Therefore, we investigated
whether Apollo-GFP can be delocalized from telomeres
upon treatment with DNA-damaging agents, such as
cisplatin or ionizing radiations. As expected, we ob-
served an increase in the incidence of g-H2AX foci at
sites of DNA damage (Figure 2C). However, these
DNA-damage foci do not contain Apollo-GFP, which re-
mains colocalized with TRF2 (Figure 2C). Furthermore,
Apollo knockdown does not modify the number of
DNA-damage foci upon g-ray irradiation (data not
shown). These findings might argue against a direct
role of Apollo in the DNA-damage response. However,
because TRF2 can be transiently associated with DNA
breaks immediately after their formation [18], it is possi-
ble that Apollo is involved in the initial stages of DNA-
damage recognition, processing, or both.
Apollo Cooperates with TRF2 to Protect Telomeres
from the DNA-Damage Response and Fusion
A panel of four interfering RNA sequences (named CL2,
CL5, CL6, and CL11) were selected for their ability to re-
duce Apollo expression, as monitored at the mRNA and
protein levels (Figure S2). One of them (CL11) targets the
30 UTR of the gene and does not reduce the expression
of Flag-Apollo or Apollo-GFP, although it leads to
a marked reduction in Apollo mRNA level (Figure S2
and data not shown). A 2-fold reduction in the level of
Apollo mRNA in cells selected for the expression of
shRNAs corresponding to the CL2 and CL6 sequences
correlates with a slight increase in radiosensitivity
(data not shown), a previously reported consequence
of Apollo knockdown [10]. In summary, our knockdown
conditions reduce Apollo mRNA and protein levels butdo not lead to a complete extinction of Apollo expres-
sion. In all the experiments presented hereafter, the level
of Apollo mRNA inhibition is systematically indicated.
Because Apollo interacts with TRF2, we investigated
whether it could modulate the cellular and telomere
phenotypes triggered by the loss of TRF2. We infected
HT1080 cells with a lentiviral vector that was either empty
or expressed TRF2DBDM. On the same day, we trans-
fected these cells either with one of the siRNAs vali-
dated to reduce Apollo expression or with siRNA that tar-
geted the luciferase gene (siLuc) as a negative control.
This procedure was repeated after 2 days (Figure S3A).
To confirm the observed phenotype, we cotransfected
the aforementioned Apollo-GFP gene, whose expres-
sion is not inhibited by the 30UTR CL11 siRNA.
In cells infected with the empty lentiviral vector
(pWPIR), only siCL2 reduces the growth rate (Figure S3B
and data not shown). This correlates with the fact that
siCL2 triggers the highest level of Apollo inhibition (Fig-
ure S2). Interestingly, siCL2-treated cells exhibit a slight
but detectable increase in the frequency of telomere-
induced DNA-damage foci (TIFs), as manifested by an
increase in the number of nuclear foci containing both
TRF1 and 53BP1 (Figure 3A). The fact that the more
efficient siRNA causes only a modest telomeric depro-
tection suggests that a potent inhibition of Apollo is
required to trigger a detectable telomere dysfunction.
Alternatively, although less likely, off-target effects spe-
cific of siCL2 could lead to telomere deprotection inde-
pendently of Apollo inhibition.
By contrast, we observed important growth defects
triggered by Apollo knockdown in TRF2-compromised
cells (Figure S3C). The fact that all the tested siRNAs
against Apollo behave similarly makes off-target effects
highly unlikely. Furthermore,Apollo-GFP expression, re-
sistant to siCL11 (Figure S2), rescues the growth defect
due to this siRNA (Figure 3C), showing that the growth
alteration caused by siCL11 transfection is specifically
due to a reduced expression of Apollo.
The severe growth phenotype of cells altered for TRF2
and Apollo correlates with a higher incidence of a DNA-
damage response at telomeres (Figures 3B and 3C). This
increase is observed with the four siRNAs directed
againstApollo and is rescued byApollo-GFP expression
in cells transfected with siCL11 (Figure 3C).
Apollo knockdown also significantly increases the
frequency of telomeric fusion observed after TRF2 in-
hibition in metaphase spreads (Figures 3D and 3E).Figure 3. Knockdown of Apollo Increases the Telomere Dysfunction Induced by TRF2DBDM
(A) Quantification of TIFs in the indicated HT1080 cells. Cells were fixed 2 days after the first introduction of siRNAs and lentiviruses. The mean
numbers of TIFs per nuclei and the percentages of cells with four or more TIFs are represented on the graph. The numbers in brackets represent
the numbers of nuclei counted in each condition. The level of Apollo mRNA inhibition is indicated below the graph.
(B) Detection of TIFs. The indicated HT1080 cells were fixed 3 days after the second round of siRNAs and lentivirus treament. IF was performed
with TRF1 (red) and 53BP1 (green) antibodies. DNA was stained with Toto-3.
(C) Quantification of the number of TIFs in the indicated HT1080 cells. Numbers in brackets represent the numbers of nuclei counted in each
condition. An asterisk (*) indicates a p value < 0.05 in comparison with SiLuc- and TRF2DBDM-expressing cells (Student’s-t test). Also indicated
below the bar is the level of Apollo mRNA inhibition.
(D) Metaphase spreads from the HT1080 cells expressing the indicated siRNAs and infected with the indicated lentiviruses. Telomeric DNA was
stained by hybridization with a fluorescently labeled PNA (CCCTAA) probe.
(E) Quantification of the telomere fusion frequency for 100 chromosomes. The numbers in brackets represent the numbers of chromosomes
counted in each condition, and an asterisk indicates a p value < 0.01 (chi2 test).
(F) Analysis of telomere restriction fragments in the HT1080 cells treated with the indicated siRNAs and lentiviruses. HinfI- and RsaI-digested
genomic DNA was fractionated on agarose gel. After blotting, the telomeric DNA was detected with a TTAGGG repeat probe. The position of
the telomere fusions is indicated on the right of the gel.
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Exonuclease Activity In Vitro
(A) Activity of the Apollo protein on a 50-la-
beled single-stranded DNA in comparison
with the 30-to-50 E. coli Exonuclease I (lane
6), the 50-to-30 exonuclease RecJf (lane 7),
and the control sample (lane 8). The quanti-
ties of Apollo were 0.90 ng, 1.75 ng, 8.75 ng,
and 17.5 ng. The control sample was per-
formed with the highest dilution of the protein
sample.
(B) The immuno-depletion of TRF2 decreases
the DNA 50 exonuclease activity. Five hun-
dred nanograms of TEV1-digested Apollo
was incubated 4 hr with protein G sepharose
in a total volume of 200 ml in 50 mM Tris pH8,
50 mM NaCl, 0.5 mM EDTA (lane 1), and with 1
mg of purified Xpress-TRF (lane 3) or both
(lane 4) After incubation, the supernatant
was tested for exonucleolytic activity on
ssTelT (5 nM). Lanes 5 and 6 correspond to
experiments performed without Apollo (lane
5) or with the control sample (lane 6). Lane 7
shows the undigested probe. We performed
this experiment by analyzing the exonuclease
activity remaining in the sample after TRF2
immunoprecipitation with an antibody raised
against the Xpress epitope (Invitrogen) that
was added to the TRF2 N-terminal sequence.
Immunoblotting experiments showed a sig-
nificant enrichment of TRF2 in the Xpress
immunoprecipitates (data not shown). We es-
timated that the experimental error of the per-
centage of cleaved DNA is less than 10%.
(C) Same experiment as that in (A), but the
probe was double stranded and contained
a 30 telomeric overhang. Labeling was per-
formed on the 50 end of the top strand.
(D) Same experiment as that in (C), but the
probe was labeled at the 50 end of the bottom
strand.As previously documented [5], these fusions can appear
as telomeric restriction fragments, which migrate at
twice the original mean length. Although these telomeric
restriction fragments are barely detectable in TRF2-
compromised HT1080 cells, their intensity markedly in-
creased upon Apollo knockdown in cells expressing
TRF2DBDM but not in control cells (Figures 3F and
S4A). We also observed a reduction of these telomeric
fusion fragments upon the expression of Apollo-GFP in
siCL11-treated cells (Figure 3F). These results are in
complete agreement with the analysis of the number of
telomeric fusions in metaphase spreads (Figures 3D
and 3E) and further confirm thatApollo-GFP expression,
resistant to siCL11, rescues the telomeric phenotype of
Apollo knockdown. Inhibition of Apollo in a TRF2DBDMbackground is unlikely to cause telomeric dysfunction
through telomere shortening because neither long-
term shRNA-mediated partial inhibition in SV40-hTERT
fibroblasts nor stronger transient knockdown of Apollo
in HT1080 and HeLa cells led to a detectable change in
telomere length (Figure S4 and data not shown). Impor-
tantly, transfections with Apollo siRNAs do not modify
the protein level of TRF2DBDM or endogenous TRF2
(data not shown), ruling out the possibility that the in-
creased sensitivity of Apollo-compromised cells to
TRF2 inhibition is due to an upregulation of the domi-
nant-negative form of TRF2 or to a downregulation of
endogenous TRF2. In conclusion, these results show
that reduced expression of Apollo in TRF2-compro-
mised cells intensifies the DNA-damage response at
The Apollo 50 Exonuclease Caps Human Telomeres
1309telomeres and increases the incidence of telomere fu-
sions, providing strong evidence for an important role
for Apollo in protecting telomeres.
Apollo Exhibits a DNA 50 Exonuclease Activity
In order to gain insight on the molecular mechanisms by
which Apollo protects telomeres from the DNA-damage
response, we purified a protein version presenting
a 6xHis tag at the N terminus and a subsequent site of
cleavage for the Tobacco Etch Virus protease 1 (TEV1)
(named His-Apollo, Figure S5). The fraction eluted from
a Nickel column, which contained His-Apollo, was sub-
sequently treated with TEV1 to remove the N-terminal
tag (this fraction is labeled ‘‘Apollo’’ in Figure 4). The
TEV1-treated fraction exhibits a DNA 50-to-30 exonucle-
ase activity, which released the 50 label as a mononucle-
otide and which is indistinguishable from the one ob-
tained for the RecJf enzyme [19] (Figure 4, lanes 1–7,
and Figure S5). An extract made with the vector alone
does not show this DNA 50 exonuclease activity (Fig-
ure 4A lane 8). Furthermore, the immunodepletion of
a purified TRF2 protein added to the Apollo fraction sig-
nificantly decreases the exonuclease activity (Figure 4B).
These results are consistent with the model in which
Apollo interacts with TRF2 and exhibits a 50 exonuclease
activity.
Purified His-Apollo with an intact N-terminal His tag
showed reduced nuclease activity when it was com-
pared to the same fraction treated with TEV1 (Fig-
ure S5D). Therefore, the His-tag version of Apollo be-
haves as a partial nuclease mutant, showing that the
exonuclease activity depends upon Apollo integrity.
This observation is in agreement with previously pub-
lished results concerning the yeast Snm1 protein, whose
b-lactamase domain must be unblocked at its N ter-
minus to exhibit a full activity [20].
Double-stranded DNA substrates, either blunt or with
a 30 overhang, are also digested from their 50 end by
Apollo, although the amount of cleavage is clearly lower
than with single-strand substrates (Figures 4C–4D). Of
note, DNA substrates composed of telomeric sequences
do not appear to be preferentially cleaved by Apollo, ei-
ther as single-strand or as double-strand DNA (Figures
4C and 4D). No endonucleolytic activity is detected
with a 30-labeled double-stranded probe (data not
shown), although one cannot rule out such an activity
after in vivo modification or molecular interactions.
Overall, we conclude that recombinant Apollo, as pre-
pared here, encodes a DNA 50 exonuclease activity. This
is consistent with the important homology existing
between the N-terminal domain of Apollo and the b-lac-
tamase domain of Artemis.
Conclusions
In this report we have identified Apollo in humans as
a telomere component that is recruited by TRF2. When
Apollo expression is inhibited in TRF2-compromised
cells, the consequences of TRF2 loss are exacerbated;
such consequences include growth defects, telomere
deprotection, and increased fusions. We conclude
that Apollo cooperates with TRF2 to protect telomeric
DNA from being recognized and processed by the
DNA-repair machinery. In agreement with these data,
M. van Overbeek and T. de Lange show that a reducedactivity of Apollo induces a telomere-damage response
[21] .
The 50 exonuclease activity of Apollo raises the possi-
bility that this protein contributes to the resection that
occurs in the 50 C-rich strand of telomeric DNA during
replication [22]. Interestingly, this activity might be con-
trolled by TRF2 (this work and [23, 24]). Therefore, it
would be of great interest to investigate the role of
Apollo in G-tail length regulation and in the differential
processing of the two daughter strands.
Overall, our findings uncover an unsuspected role for
the 50 exonuclease Apollo in telomere protection and
chromosome stability.
Supplemental Data
Supplemental Experimental Procedures and figures are available
with this article online at http://current-biology.com/cgi/content/
full/16/13/1303/DC1/.
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